Investigating the Effect of Topical Imiquimod on Sebaceous Hyperplasia

Inclusion Criteria:

• Patient has sebaceous hyperplasia lesions on both sides of the face. At least onesebaceous hyperplasia lesion on each side of the face is 1 mm or more in size.

• If of child-bearing potential, subject agrees to the use of highly effectivecontraception during study participation. For women of childbearing potential,acceptable pregnancy prevention measures will include abstinence, barrier methods,chemical methods, or surgical.

• Ability to understand and willingness to sign a written informed consent

Exclusion Criteria:

• Current use or prior use of a retinoid (e.g. tretinoin) within the last 4 weeks.

• Prior use of imiquimod on the treated area.

• Concurrent use of 5-fluorouracil, aminolevulinic acid (photodynamic therapy), orpsoralen therapy, or use of any of these within the last 4 weeks.

• Concurrent facial peels or cosmetic laser therapy on the treated areas.

• Nursing, pregnant or planning to become pregnant.

• Immunocompromised status (e.g. organ transplantation recipients or patients oncyclosporine).

• Current participation in other investigational trials.

• Known or suspected history of a clinically significant systemic disease (e.g.,immunological deficiencies), unstable medical disorders (e.g., unstable diabetes),life-threatening disease or current malignancies.

• Known hypersensitivity to any of the following (in any dosage form): imiquimod orany component of the study medications.

• Received radiation therapy and/or anti-neoplastic agents within 3 months prior tostudy entry.